Mammalian cell-based production of glycans, glycopeptides and glycomodules

Thapakorn Jaroentomeechai, Richard Karlsson, Felix Goerdeler, Fallen Kai Yik Teoh, Magnus Nørregaard Grønset, Dylan Wit, Yen-Hsi Chen, Sanae Furukawa, Venetia Psomiadou, Ramon Hurtado-Guerrero, Elena Ethel Vidal-Calvo, Ali Salanti, Thomas J. Boltje, Leendert J. Bos, Christian Wunder, Ludger Johannes, Katrine T. Schjoldager, Hiren J. Joshi, Rebecca L. Miller, Henrik Clausen, Sergey Y. Vakhrushev and Yoshiki Narimatsu ()
Additional contact information
Thapakorn Jaroentomeechai: University of Copenhagen
Richard Karlsson: University of Copenhagen
Felix Goerdeler: University of Copenhagen
Fallen Kai Yik Teoh: University of Copenhagen
Magnus Nørregaard Grønset: University of Copenhagen
Dylan Wit: University of Copenhagen
Yen-Hsi Chen: GlycoDisplay ApS
Sanae Furukawa: University of Copenhagen
Venetia Psomiadou: Radboud University Nijmegen
Ramon Hurtado-Guerrero: University of Copenhagen
Elena Ethel Vidal-Calvo: University of Copenhagen, Copenhagen University Hospital
Ali Salanti: University of Copenhagen, Copenhagen University Hospital
Thomas J. Boltje: Radboud University Nijmegen
Leendert J. Bos: EnzyTag BV
Christian Wunder: PSL Research University, U1143 INSERM, UMR3666 CNRS
Ludger Johannes: PSL Research University, U1143 INSERM, UMR3666 CNRS
Katrine T. Schjoldager: University of Copenhagen
Hiren J. Joshi: University of Copenhagen
Rebecca L. Miller: University of Copenhagen
Henrik Clausen: University of Copenhagen
Sergey Y. Vakhrushev: University of Copenhagen
Yoshiki Narimatsu: University of Copenhagen

Nature Communications, 2024, vol. 15, issue 1, 1-16

Abstract: Abstract Access to defined glycans and glycoconjugates is pivotal for discovery, dissection, and harnessing of a range of biological functions orchestrated by cellular glycosylation processes and the glycome. We previously employed genetic glycoengineering by nuclease-based gene editing to develop sustainable production of designer glycoprotein therapeutics and cell-based glycan arrays that display glycans in their natural context at the cell surface. However, access to human glycans in formats and quantities that allow structural studies of molecular interactions and use of glycans in biomedical applications currently rely on chemical and chemoenzymatic syntheses associated with considerable labor, waste, and costs. Here, we develop a sustainable and scalable method for production of glycans in glycoengineered mammalian cells by employing secreted Glycocarriers with repeat glycosylation acceptor sequence motifs for different glycans. The Glycocarrier technology provides a flexible production platform for glycans in different formats, including oligosaccharides, glycopeptides, and multimeric glycomodules, and offers wide opportunities for use in bioassays and biomedical applications.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-53738-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53738-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-53738-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().